Vical Initiates Pivotal Phase 3 Trial Of Allovectin-7(R) As First-line Therapy For Metastatic Melanoma

Vical Incorporated (Nasdaq: VICL) announced today the initiation of a Phase 3 pivotal trial of the company’s Allovectin-7(R) cancer immunotherapeutic as first-line therapy in chemotherapy-naive patients with recurrent Stage III or IV metastatic melanoma. The trial, known as AIMM (Allovectin-7(R) Immunotherapeutic for Metastatic Melanoma), will be conducted in accordance with a Special Protocol Assessment (SPA) completed with the U.S. Food and Drug Administration (FDA) at up to 50 clinical sites. AnGes MG, Inc., will fund the clinical trial under a collaborative agreement with Vical.

“We are excited to begin the AIMM head-to-head superiority trial against first-line chemotherapy,” said Robin M. Jackman, Senior Vice President of Business Operations at Vical. “There is a great need for new treatment options in metastatic melanoma, where no new first-line therapies have been approved in nearly 15 years. With a primary endpoint of durable response rate, we can complete the trial after scheduled follow-up for the last patient without having to wait for long-term survival data. We are working aggressively to enroll patients into this trial and advance this novel product toward commercialization in collaboration with AnGes.”

Because of substantial unmet medical need, Allovectin-7(R) has been granted orphan drug designation for the treatment of invasive and metastatic melanoma by the FDA’s Office of Orphan Products Development. Orphan drug designation provides U.S. marketing exclusivity for seven years upon marketing approval by the FDA, in addition to certain tax benefits for qualifying expenses.

The AIMM trial calls for enrollment of approximately 375 patients with recurrent metastatic melanoma. Patients may have been previously treated with surgery, adjuvant therapy, and/or biotherapy, but cannot have been previously treated with chemotherapy. The patients will be randomized on a 2:1 basis: approximately 250 patients will be treated with Allovectin-7(R) and approximately 125 will be treated with their physician’s choice of either of two chemotherapy agents, dacarbazine or temozolomide. The primary endpoint is a comparison of objective response rates at six months or more after randomization. The study will also evaluate safety and tolerability as well as survival. Further information on the trial is available through the company’s web site at http://www.vical.com or at the National Institutes of Health (NIH) clinical trials web site at http://www.clinicaltrials.gov.

About the Author

admin has written 6390 stories on this site.

Write a Comment

Gravatars are small images that can show your personality. You can get your gravatar for free today!

You must be logged in to post a comment.

Copyright © 2009 Medical News. All rights reserved.
Powered by WordPress.org, Custom Theme and ComFi.com Calling Card Company.
Close